国产热热热精品,亚洲视频久久】日韩,三级婷婷在线久久,99人妻精品视频,精品九热人人肉肉在线,AV东京热一区二区,91po在线视频观看,久久激情宗合,青青草黄色手机视频

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

Bayer's $60m investment to boost capacity, reaffirm its commitment to China

chinadaily.com.cn | Updated: 2020-08-28 16:51
Share
Share - WeChat
Bayer today announces to launch the capacity expansion project of its Pharmaceuticals Product Supply Beijing site for addressing further demand of its drug products in China. [Photo provided to chinadaily.com.cn]

Bayer today announces to launch the capacity expansion project of its Pharmaceuticals Product Supply Beijing site for addressing further demand of its drug products in China. With an investment of more than 50 million euros ($59.52 million), the planned project is designated to increase the production capacity and accelerate the implementation of innovative digital solutions at the Beijing site, aiming to ensure a reliable supply of high-quality prescription drugs for more Chinese patients. Representatives from China's Ministry of Commerce, Germany Embassy, Beijing Municipal Government and the Beijing Economic-Technological Development Area attended the ceremony.

"We are very pleased to see that this project marks the latest milestone of Bayer's development journey in China, which is also a new start for us to consistently deliver our high-quality products and benefit more Chinese patients in need," said Wei Jiang, executive vice-president and president of Bayer Pharmaceuticals Region China & APAC and president of Bayer Group Greater China. "In the face of huge challenges caused by the COVID-19 pandemic, the initiative fully demonstrates Bayer's unswerving confidence and commitment to China, and again shows our aspiration of serving more Chinese patients and determination to contribute to building a healthy China."

The new production lines are expected to become operational at the end of 2022. Then the estimated annual output of the Beijing Site can be increased by about 40 percent, which will again reinforce its position among the most advanced production sites of Bayer Pharmaceuticals' global network.

Cardiovascular diseases and diabetes remain among major chronic diseases which are prioritized by the Chinese central government in its Healthy China Action Plan in efforts to address major health challenges caused by the prevalence of chronic diseases. In addition, the COVID-19 pandemic reinforces the significance of a reliable, resilient drug supply chain to the country's public health as well as well-beings of Chinese people.

The expansion project covers production area and related technical area, which is designed as a world-class manufacturing facility. It includes new high-speed production lines in combination with a sophisticated logistics system.

Bayer today announces to launch the capacity expansion project of its Pharmaceuticals Product Supply Beijing site for addressing further demand of its drug products in China. [Photo provided to chinadaily.com.cn]
Top
BACK TO THE TOP
English
Copyright 1994 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
荣昌县| 长顺县| 芜湖市| 辉南县| 通道| 冷水江市| 宿迁市| 湟中县| 鹤壁市| 土默特左旗| 桐乡市| 普定县| 招远市| 中宁县| 赣州市| 榕江县| 宁武县| 龙口市| 湟中县| 准格尔旗| 靖西县| 新竹县| 呼玛县| 乐昌市| 合阳县| 尚义县| 穆棱市| 兴宁市| 梁河县| 昭苏县| 乌海市| 禹城市| 成都市| 绥江县| 中卫市| 石河子市| 东乌珠穆沁旗| 永仁县| 积石山| 江华| 海淀区|